<DOC>
	<DOCNO>NCT01596725</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety profile Avian flu vaccine without adjuvant 2 healthy , young adult . The study divide Parts A1 , A2 B . Groups within Part receive two dos assign test article Study Days 0 21 . There Safety Monitoring Committee assessment follow Day 7 part , prior allow vaccination subject subsequent Parts study .</brief_summary>
	<brief_title>A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Healthy adult male female , ≥18 ≤49 year age , 2 . Willing able give inform consent prior study enrollment , 3 . Able comply study requirement , 4 . All woman must negative urine pregnancy test prior vaccination . Women advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history abstinence heterosexual activity prior surgical sterilization , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , doublebarrier contraceptive ( condom diaphragm , spermicide ) , intrauterine device ( IUD ) . 1 . Any ongoing , symptomatic acute chronic illness require medical surgical care . Asymptomatic condition ( e.g. , hypertension , dyslipidemia ) manage medically associate evidence endorgan damage exclusionary provide clinically stable ( define unscheduled medical intervention change medication cause within 3 month ) . 2 . Any history jaundice , hepatic injury due drug ( prescription , OTC , illicit ) alcohol use viral hepatitis ; presence hepatitis B surface antigen hepatitis C antibody screen . 3 . Any grade 1 high ( base Toxicity Grading Scale [ TGS ] ) abnormality serum glutamicpyruvic transaminase/alanine aminotransferase ( SGPT/ALT ) , serum glutamicoxaloacetic transaminase/aspartate aminotransferase ( SGOT/AST ) , alkaline phosphatase , total bilirubin level . 4 . Any grade 2 high ( base TGS ) vital sign clinical laboratory abnormality specify criterion 3 . Note abnormal vital sign may repeat Investigator 's discretion . 5 . Participation research involve investigational product ( drug / biologic / device ) within 45 day plan date first vaccination . 6 . History serious reaction prior influenza vaccination . 7 . History GuillainBarré Syndrome ( GBS ) within 6 week follow previous influenza vaccine . 8 . Received vaccine 4 week precede study vaccination ; A/H5N1 avian influenza vaccine time . 9 . Any known suspected immunosuppressive condition , acquire congenital , include HIV infection , determine history and/or physical examination . 10 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10 mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 11 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 12 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration ) . 13 . Known disturbance coagulation . 14 . Women pregnant breastfeeding , plan become pregnant study . 15 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse . 16 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic psychiatric condition deem likely impair quality safety reporting ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>